AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02455518 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen/acetaminophen
Study NCT02309138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gestational diabetes screening with fasting 3 hour 100 gm
Description: Participants receive fasting 3 hour 100 gm oral glucose tolerance test
Study NCT02309138 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Gestational diabetes screening with fasting 2 hour 75g
Description: Participants receive fasting 2 hour 75 gm oral glucose tolerance test
Study NCT01982448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study NCT01982448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Study NCT01562561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide
Description: 2 mg at each main meal
Study NCT01562561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin NPH
Description: Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
Study NCT01562561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin NPH
Description: Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
Study NCT03145389 — intervention group
Intervention type: PROCEDURE
Intervention: Epidural catheter placement
Description: After explaining about the procedure an 18 Gauge epidural catheter was inserted into thoracic 11-12 inter vertebral space under strict asepsis. Before inserting the epidural needle same space was infiltrated with adequate amount of 2% Lignocaine with Adrenaline (1: 200,000) to make the procedure pain free. Epidural space was confirmed by loss of resistance technique.
Study NCT00086281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem (X)
Description: Xyrem (Sodium Oxybate) Oral Solution
Study NCT00086281 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zolpidem (Z)
Description: Zolpidem 10 mg oral tablets
Study NCT00086281 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil (M)
Description: Modafinil Oral Tablets
Study NCT01437410 — intervention group
Intervention type: PROCEDURE
Intervention: EUS-FNA
Description: tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
Study NCT02987218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation
Study NCT02987218 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desflurane
Description: Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
Study NCT02094534 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ORMD-0801 Capsules
Description: API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
Study NCT02094534 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Fish oil capsules, identical in appearance to the experimental intervention.
Study NCT03100188 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modified PD prescription
Description: For patients on CAPD, fewer daily exchanges or fewer total weekly exchanges are prescribed. Patients on CCPD are prescribed shorter cycler time or fewer total cycles during the week.
Study NCT03926702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Radiopharmaceuticals
Description: All subjects will receive radiopharmaceutical for positron-emission tomography (PET) scan.
Study NCT00570388 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prometa Treatment Program
Description: Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol.
Study NCT00570388 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prometa Treatment Program
Description: Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.~Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.~Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN~Days 4 through 28•Gabapentin 1200 mg po 9 PM~Days 29 through 31•Gabapentin 900 mg po 9 PM~Days 32 through 34•Gabapentin 600 mg po 9 PM~Days 35 through 38•Gabapentin 300 mg po 9 PM~Flumazenil Dosing Schedule~2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol.
Study NCT02379000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone Acetonide
Description: Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
Study NCT02379000 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transpupillary thermotherapy
Description: We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.
Study NCT01005849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protecflor
Description: 1 Capsule to be taken once a day during the entire study period
Study NCT01005849 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 Capsule to be taken once a day during the entire study period
Study NCT03559205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MSK-Tracker
Description: The intervention is not a treatment, but involves patients and clinicians engaging with the MSK-Tracker software which will facilitate a new care planning approach with the following distinct components:~* Pre-clinic preparation.~* Clinic dashboard.~* Summary action plan.~* Personal goal setting.~* Follow-up and monitoring.
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 25 mg
Description: Tablet, 25 mg, once daily for 84 days
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sitagliptin 100 mg
Description: Tablet, 100 mg, once daily for 84 days
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Sitagliptin
Description: Tablet, matching placebo to 100 mg, once daily for 84 days
Study NCT00248118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: During treatment phase, participants will take 300 mg bupropion or placebo daily.
Study NCT00248118 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: During treatment phase, participants will take 300 mg bupropion or placebo daily.
Study NCT02987907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: use dexamethasone 10mg (2ml) I.A. during TACE
Study NCT02987907 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: use normal saline 2ml I.A. during TACE
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Sitagliptin
Description: Tablet, matching placebo to 100 mg, once daily for 84 days
Study NCT01059825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
Study NCT03217877 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: routine stress testing
Description: In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9\~15 months after the procedure according to the practice pattern of each participating center.
Study NCT03217877 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: No Routine stress testing
Description: In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
Study NCT03786302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAMP bioglass
Description: TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
Study NCT03786302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Biodentine
Description: TAMP bioglass compared to Biodentine in the regeneration on pulpotomized primary teeth
Study NCT03117790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
Study NCT03117790 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
Study NCT00497549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: side-to-side stapled
Description: 5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
Study NCT00497549 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: hand sewn
Description: A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
Study NCT02968160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 40mg + Rosuvastatin 20mg
Study NCT02968160 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan 80mg + Rosuvastatin 20mg
Study NCT02968160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan 40mg, 80 mg
Study NCT02968160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin 20mg
Study NCT03539289 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: MUFA Diet
Description: Control of patient MUFA Diet
Study NCT03539289 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SFA Diet
Description: Control of patient SFA Diet
Study NCT01575015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous renal replacement therapy (CRRT)
Description: Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation
Study NCT01575015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard intraoperative support
Description: Patients allocated to standard intraoperative support will receive usual care (no CRRT).
Study NCT03524755 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT02605174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 50 mg
Description: One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
Study NCT02605174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 100 mg
Description: One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)
Study NCT02605174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan 200 mg
Description: One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)
Study NCT02605174 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo tablets to match lasmiditan doses.
Study NCT01833455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PVC Suppression using Flecainide
Description: Flecainide will be administered to result in a reduction in PVC burden.
Study NCT01833455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: No PVC Suppression using Placebo
Description: Placebo (sugar pills) will be given to result in no alteration in PVC burden.
Study NCT04301206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: Empowerment of parents. When calling the medical helpline 1813 the parents will be offered to access the new material about sick children, compared to not getting this possibility.
Study NCT04598594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patch, Nicotine
Description: Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
Study NCT04598594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Patch, Placebo
Description: Two patches of 7 mg/day Treatment at 14 mg/day during mechanical ventilation since after first successful extubation then, dose decreasing: Week 1: 10,5 mg/day Week 2 : 7 mg/day Week 3 : 3,5 mg/day
Study NCT02765594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate
Description: 200mg bid
Study NCT02765594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 160mg qd
Study NCT04193761 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: taurine level
Description: Taurine: determined by High-Performance Liquid Chromatography according to the pre-column extraction and derivatization methodology of McMahon et al. in the present work we use the Shimadzu, Japan HPLC model LC-10 AT.
Study NCT00562094 — intervention group
Intervention type: DRUG
Intervention: Pantoprazole
Description: This was an observational study. Therefore, the physician decided about dosage according to individual needs.
Study NCT01121627 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computerized cognitive training
Description: A 12 week computerized cognitive training at home with the Attengo™ software program.
Study NCT01824823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: afatinib
Description: Given PO
Study NCT01824823 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given PO
Study NCT01600482 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELT ACD
Description: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
Study NCT01730456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg iv every 4 weeks, up to 104 weeks
Study NCT01448941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Temporary extraarticular plate fixation
Description: Arm 1: Primary arthrodesis TMT 1 Arm 2: Temporary extraarticular plate fixation TMT 1
Study NCT01448941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary arthrodesis
Description: Primary arthrodesis
Study NCT01448941 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary arthrodesis TMT 2 and 3
Description: Primary arthrodesis TMT 2 and 3 when instability is present
Study NCT01448941 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Primary arthrodesis TMT 2 and 3
Description: Primary arthrodesis TMT 2 and 3 when instability is present
Study NCT03723031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 microgram (2 tablets) misoprostol ( cytotec, Pfizer, G.D. Searle LLC) inserted rectally (before CS) in rectal group or intrauterine (200 microgram at each cornu) intraoperatively following the delivery of the placenta in intrauterine group.
Study NCT03293875 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Encuentro
Description: a behavioral intervention designed to increase HIV testing rates and reduce behaviors that place individuals who use drugs at risk of contracting HIV
Study NCT01128959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Carbamazepine (IV CBZ)
Description: 10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
Study NCT04347473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ilumya Injectable Product
Description: IL-23 injection
Study NCT02076269 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Intervention
Description: Patients are receiving no treatment in this study and there is no investigational product involved
Study NCT03349645 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 4 mL injection of AMPION™
Description: 4 mL injection of AMPION™
Study NCT01174277 — intervention group
Intervention type: OTHER
Intervention: Collection of blood sample
Description: Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
Study NCT01686750 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated care centers
Study NCT02378012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Computer-Assisted Intervention
Description: Receive access to Netflix, Spotify, and Skype applications
Study NCT02378012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Receive access to Netflix, Spotify, and Skype applications
Study NCT02378012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Intervention
Description: Receive iPad and instruction manuals.
Study NCT02378012 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02378012 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00521391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Allez Hop
Description: a tailored physical activity intervention involving moderate-intensity exercise
Study NCT03619928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dry needling
Description: 20 minutes through a sterile, disposable Dong Bang® needle size of 0.25X30 mm. At the moment of insertion of the needle, the therapist will perform a muscular shortening around the application site, in a pincer movement performed by the index and thumb fingers, in order to isolate the muscle fibers of the biceps brachii. Five needles will be applied to the short head brachii biceps in five points: origin, insertion, center of the muscular womb (60% of the distance from the medial acromion to the cubital fossa in the elbow line) and two points equidistant from the center 2 cm.
Study NCT03619928 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Massotherapy
Description: A 20-minute massage will be applied to the non-dominant upper limb exercised by a therapist for the massage condition. The massage will consist of: 1) surface slip; 2) deep slip; 3) kneading; 4) friction with the thumbs; 5) friction with four fingers; 6) percussions with open and alternating hands; 7) percussions with open and simultaneous hands; 8) tapping; and 9) surface slip.